Any current/future new fundraising through debt or equity?

The company has not indicated any current plans for new fundraising through debt or equity. It reported a significant reduction in gross debt from Rs.548 crore (March 2023) to Rs.427 crore (September 2023) and net debt down to Rs.18 crore. The company is generating strong cash flows (around Rs.500 crore annually). Management separates debt and M&A plans, indicating no long-term debt concerns. There is no mention of immediate equity fundraising. CAPEX plans for the year are funded from internal resources, including Rs.145 crore planned for facility expansion. Overall, the focus appears to be on

Any current/future capex/capital investment/strategic investment?

Current FY24 CAPEX guidance is Rs.145 crore, including: - Rs.50 crore for land acquisition adjacent to the current lozenges manufacturing unit (futuristic expansion). - Around Rs.70 crore is maintenance CAPEX. - Marginal expansion of granulation tablet unit. Land acquisition is in preparation for doubling manufacturing capacity over 2-3 years. No immediate plans to add new medical reps, focusing on productivity growth. Exploring expansion in international geographies like the Philippines, but no near-term costs or launches expected (1-2 years away). CDMO business is growing, aiming to do

Future growth expectations in sales/revenue/volumes?

Domestic India business is expected to grow at 12% to 14% annually, outpacing the market growth of 8%-12%. Chronic portfolio in India is growing strongly at 18%, compared to 10% market growth, and is a key growth driver. Acute portfolio growth is modest at around 6%-7%, with better traction expected in upcoming quarters. International business, excluding South Africa, grew mid-teens; overall international business expected to grow at healthy double digits (~12%) next year after South Africa base reset. CDMO business aims to reach close to $100 million revenue in about three years, supported by

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects continued healthy EBITDA margins, targeting the upper side of guidance between 25% to 27%, with ambitions to reach mid-teens growth. Domestic India business growth is forecasted at 12% to 14% for the full year, outperforming the Indian pharma market growth of 8% to 12%. Chronic segment growth remains strong at 18% year-on-year, outpacing the market’s 10%; the acute segment growth was about 6% in Q2. CDMO business aims to grow to $100 million in revenue within the next 3 years, doubling from current levels. Margin expansion potential exists beyond current 27.6%, with

IN US

Sale is live|00:00:00left today

J B Chemicals & Pharmaceuticals LtdQ3 FY23Pharmaceuticals & Biotechnology

J B Chemicals & Pharmaceuticals Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,244P/E: 47.1Market Cap: ₹34.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Domestic India business is expected to grow at 12% to 14% annually, outpacing the market growth of 8%-12%.
→Chronic portfolio in India is growing strongly at 18%, compared to 10% market growth, and is a key growth driver.
→Acute portfolio growth is modest at around 6%-7%, with better traction expected in upcoming quarters.
→International business, excluding South Africa, grew mid-teens; overall international business expected to grow at healthy double digits (~12%) next year after South Africa base reset.
→CDMO business aims to reach close to $100 million revenue in about three years, supported by new product launches and portfolio diversification.
→Volume growth in India is approximately 5%-6%, balanced evenly with pricing growth.
→New launches, especially in CDMO, expected in the second half of next year, supporting future growth.
→The company targets increasing contribution from India and CDMO to 75%-80% of overall sales in mid to long term.

Margin guidance

Category 3

→The company expects continued healthy EBITDA margins, targeting the upper side of guidance between 25% to 27%, with ambitions to reach mid-teens growth.
→Domestic India business growth is forecasted at 12% to 14% for the full year, outperforming the Indian pharma market growth of 8% to 12%.
→Chronic segment growth remains strong at 18% year-on-year, outpacing the market’s 10%; the acute segment growth was about 6% in Q2.
→CDMO business aims to grow to $100 million in revenue within the next 3 years, doubling from current levels.
→Margin expansion potential exists beyond current 27.6%, with margin improvements driven by higher chronic mix, rationalization of low-margin business, and CDMO contributions.
→No immediate plans to add field force; focus is on enhancing productivity and organic growth plus selective bolt-on acquisitions for synergy and growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company has not indicated any current plans for new fundraising through debt or equity.
→It reported a significant reduction in gross debt from Rs.548 crore (March 2023) to Rs.427 crore (September 2023) and net debt down to Rs.18 crore.
→The company is generating strong cash flows (around Rs.500 crore annually).
→Management separates debt and M&A plans, indicating no long-term debt concerns.
→There is no mention of immediate equity fundraising.
→CAPEX plans for the year are funded from internal resources, including Rs.145 crore planned for facility expansion.
→Overall, the focus appears to be on organic growth, selective inorganic acquisitions funded via internal accruals, and maintaining a strong balance sheet rather than raising new external capital.

Order book

The transcript provided on page 15 and surrounding pages does not specifically mention details about the current or expected order book or pending orders for J.B. Chemicals & Pharmaceuticals Limited. The discussion focuses more on business segments, growth, margins, acquisitions, geographic expansion, and product pipeline. Key points related to business outlook but not specific order book details: - India and CDMO businesses expected to contribute close to 75%-80% of overall sales in the mid to long term. - CDMO business aiming to reach $100 million revenue in around 3 years. - India business growing at 12%-14%, with chronic therapies and acquired portfolios driving growth. - No specific quantitative disclosure on current or expected order backlog or pending orders. Therefore, no explicit data on order book or pending orders is available in the provided transcript.

Capex plans

Yes

→Current FY24 CAPEX guidance is Rs.145 crore, including:
→ - Rs.50 crore for land acquisition adjacent to the current lozenges manufacturing unit (futuristic expansion).
→ - Around Rs.70 crore is maintenance CAPEX.
→ - Marginal expansion of granulation tablet unit.
→Land acquisition is in preparation for doubling manufacturing capacity over 2-3 years.
→No immediate plans to add new medical reps, focusing on productivity growth.
→Exploring expansion in international geographies like the Philippines, but no near-term costs or launches expected (1-2 years away).
→CDMO business is growing, aiming to double revenue to $100 million in mid to long term via portfolio expansion, new geographies, cost savings, and new product launches.
→Company remains open to inorganic growth via bolt-on acquisitions aligned with strategic focus, maintaining a payback period target of under 6 years.

How does J B Chemicals & Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1J B Chemicals & Pharmaceuticals Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like J B Chemicals & Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio